



Supplementary figure 1. Changes in treatment based on TDM supported or empirical decision

Therapy	Package	Dose	Total cost/year	Cost per dosage/doses per year
Infliximab	1 vial powder 100 mg	5 mg/kg i.v. every 8 weeks	€14.983*	€2.305/6.5
70% Infliximab	1 vial powder 100 mg	3.5 mg/kg i.v. every 8 weeks	€10.491*	€1.614/6.5
130% Infliximab	1 vial powder 100 mg	6.5 mg/kg i.v. every 8 weeks	€19.481*	€2.997/6.5
Adalimumab	2 syringes 40 mg	40 mg every 2 weeks	€16.822	€647/26
Adalimumab (67%)	2 syringes 40 mg	40 mg every 3 weeks	€10.999	€647/17
Adalimumab (150%)	2 syringes 40 mg	40 mg every week	€33.644	€647/52
Etanercept	4 syringes 50 mg	50 mg every week	€17.524	€337/52
Etanercept (70%)	4 syringes 50 mg	50 mg every 10 days	€12.132	€337/36
Etanercept (140%)	4 syringes 50 mg	50 mg every 5 days	€24.601	€337/73
Golimumab	1 syringe 50 mg	50 mg every month	€20.052	€1671/12
Certolizumab	2 syringes 200 mg	200 mg every 2 weeks	€17.212	€662/26
<u>Non-TNFi biologics</u>				
Tocilizumab	4 syringes 162 mg	162 mg every week	€18.460	€710/52
Abatacept	1 syringe 125 mg	125 mg every week	€ 19.188	€369/52
Secukinumab	1 syringe 150 mg	150 mg every month	€ 8.604	€717/12
Tofacitinib	56 tablets 5 mg	10 mg every day	€ 14.677	€1.129/13
Ixekizumab	1 syringe 80 mg	80 mg every month	€18.252	€1.546/12

Supplementary Table 1. Therapy cost of the different treatment strategies.

*Dependent on body weight. The prices for infliximab in the table are standardized to a body weight of 70 kg, equivalent of 350 mg every 8 weeks as standard treatment

	All (n=306)	TDM guided (n=111)	Empiric guided (n=195)
Infliximab, n	67	27	40
In remission/low disease activity, n (%)	49 (73)	20 (74)	29 (69)
Loss of response, n (%)	14 (21)	5 (19)	9 (21)
Adverse events, n (%)	4 (6)	2 (7)	2 (5)
Adalimumab, n	63	30	33
In remission/low disease activity, n (%)	48 (75)	26 (87)	22 (65)
Loss of response, n (%)	9 (14)	4 (13)	5 (15)
Adverse events, n (%)	6 (9)	0 (0)	6 (18)
Etanercept, n	137	46	91
In remission/low disease activity, n (%)	90 (65)	35 (76)	55 (59)
Loss of response, n (%)	36 (26)	10 (22)	26 (28)
Adverse events, n (%)	11 (8)	1 (2)	10 (11)
Golimumab, n	39	8	31
In remission/low disease activity, n (%)	30 (77)	8 (100)	22 (71)
Loss of response, n (%)	7 (18)	0 (0)	7 (23)
Adverse events, n (%)	2 (5)	0 (0)	2 (6)

Supplementary Table 2. Clinical response at two years follow-up